Anal Fistula Market

Market Overview:

The 7 major anal fistula markets are expected to exhibit a CAGR of 3.4% during 2024-2034.

The anal fistula market has been comprehensively analyzed in IMARC's new report titled "Anal Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anal fistula is an abnormal tunnel or tract that forms between the anal canal or rectum and the skin surrounding the anus. It can vary in complexity, with some being straightforward and others more intricate with multiple tracts. The common symptoms associated with the ailment include persistent or recurrent pain around the anus, particularly during bowel movements, discharge of pus or blood from the opening near the anus, swelling or a lump near the anal region, itching or irritation around the anal area, and occasionally, fever. The specific indications experienced may vary depending on the characteristics of the fistula, and some patients may have minimal or no signs at all. Diagnosing an anal fistula typically involves a thorough examination by a healthcare professional, such as a colorectal surgeon. The diagnosis is made through a combination of physical exam and medical history review. The healthcare provider may visually inspect the anal area, looking for signs of an opening or discharge. Additional diagnostic tests, including endoanal ultrasound or magnetic resonance imaging (MRI), are also performed to visualize the fistula tract, determine its characteristics, and evaluate any underlying causes.

The escalating incidences of inflammation in the digestive tract that can weaken the tissues, impair healing, and create abnormal connections or tunnels between the anal canal or rectum and the surrounding skin, are primarily driving the anal fistula market. In addition to this, the rising cases of injuries or trauma to the anal or rectal area, such as during childbirth and surgery, infections in the perianal region, previous surgical procedures involving the anus or rectum, anal abscesses, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of fistula plugs made of biological or synthetic materials, since they offer a less invasive option with the potential for quicker healing and reduced recurrence rates, is further bolstering the market growth. Apart from this, the inflating application of intersphincteric fistula tract (LIFT) procedure that involves identifying and ligating the internal opening of the fistula and removing the diseased tissue is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive techniques, such as video-assisted anal fistula treatment (VAAFT) and endoanal ultrasound-guided therapy (EUA), which allow for precise identification of the fistula tract and targeted intervention while minimizing tissue damage, is expected to drive the anal fistula market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the anal fistula market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for anal fistula and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anal fistula market in any manner.

Key Highlights:

• Anal fistulas account for over 70% of perianal illnesses that require surgical treatment and occur in 1:10,000 people each year.
• The incidence of an anal fistula emerging from an anal abscess is between 15 and 38%.
• The average age for the manifestation of anal fistula is 40 years (range 20-60).
• Adult males are twice as probable to develop an anal fistula as women.
• The overall prevalence of anal fistula in European countries was 18.37 per 100,000 people.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034 
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the anal fistula market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the anal fistula market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current anal fistula marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance 
    

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the anal fistula market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the anal fistula market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the anal fistula market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of anal fistula across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of anal fistula by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of anal fistula by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with anal fistula across the seven major markets?
• What is the size of the anal fistula patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of anal fistula?
• What will be the growth rate of patients across the seven major markets?

Anal Fistula: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for anal fistula drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anal fistula market?
• What are the key regulatory events related to the anal fistula market?
• What is the structure of clinical trial landscape by status related to the anal fistula market?
• What is the structure of clinical trial landscape by phase related to the anal fistula market?
• What is the structure of clinical trial landscape by route of administration related to the anal fistula market?